Should I Buy CRDF? CRDF 2026 Analysis

Should You Buy Cardiff Oncology Inc (CRDF) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.210

1 Day change

2.54%

52 Week Range

4.550

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cardiff Oncology Inc (CRDF) is not a good buy for a beginner investor with a long-term strategy at this time. The stock faces significant uncertainties due to ongoing litigation over its sole asset, onvansertib, and lacks positive financial or technical indicators. Analysts have downgraded the stock, and the technical analysis suggests a bearish trend. Additionally, there are no strong trading signals or positive catalysts to justify an entry point.

Technical Analysis

The technical indicators are bearish. The MACD histogram is negative and expanding, RSI is neutral but leaning toward oversold territory, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 1.112.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The options data shows a very low put-call ratio, indicating minimal bearish sentiment in the options market. However, the implied volatility is extremely high (501.55%), suggesting significant uncertainty and risk.

Technical Summary

Sell

Buy

Positive Catalysts

NULL. There are no recent news updates, and hedge fund and insider trading trends are neutral. Analysts believe the ownership dispute may be resolved in the near term, but this is speculative.

Neutral/Negative Catalysts

The ongoing litigation with Nerviano Medical Sciences over the ownership of onvansertib creates significant uncertainty. Analysts have downgraded the stock, citing concerns over financing and ownership of its sole asset. Technical indicators and stock trend analysis suggest a bearish outlook.

Financial Performance

No financial data or valuation metrics are available for analysis. The lack of financial transparency adds to the uncertainty.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is negative. Multiple firms have downgraded the stock from Buy to Hold or Neutral, and price targets have been significantly lowered (e.g., from $10 to $2 or $4). Analysts cite litigation and financing concerns as key reasons for the downgrades.

6 Analyst Rating

Wall Street analysts forecast CRDF stock price to rise

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.180

Low

Averages

13.67

High

Current: 1.180

Low

Averages

13.67

High

Lucid Capital

Christopher Liu

Buy

downgrade

$10 -> $4

AI Analysis

2026-06-05

Reason

Lucid Capital

Christopher Liu

Price Target

$10 -> $4

AI Analysis

2026-06-05

downgrade

Buy

Reason

Lucid Capital analyst Christopher Liu lowered the firm's price target on Cardiff Oncology to $4 from $10 and keeps a Buy rating on the shares. The company's licensor dispute with Nerviano Medical Sciences puts the ownership of onvansertib into question, the analyst tells investors in a research note. However, the firm believes both parties are "highly motivated to resolve the issue in the near-term." Lucid says Cardiff shares may recover as onvansertib's data "comes back into the forefront of the story."

Craig-Hallum

Buy

Hold

downgrade

$10 -> $2

2026-06-03

Reason

Craig-Hallum

Price Target

$10 -> $2

2026-06-03

downgrade

Buy

Hold

Reason

As previously reported, Craig-Hallum downgraded Cardiff Oncology to Hold from Buy with a price target of $2, down from $10. The firm notes the company presented an update from onvansertib's ongoing Phase II study in first line RAS-mutated metastatic colorectal cancer at Asco. The median progression-free survival in the onvansertib 30 mg plus FOLFIRI/bevacizumab arm was not reached, compared to 11.22 months in the FOLFIRI/bevacizumab control arm, with a hazard ratio of 0.57. Although the sample size was small, the positive progression-free survival data supports advancing to the planned Phase III study. Craig-Hallum is moving to the sidelines as it believes the pending litigation around the license agreement dispute creates an overhang on near-term financing plans to initiate the Phase III study.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRDF

Unlock Now

CRDF Should I Buy

CRDF Should I Buy

Should You Buy Cardiff Oncology Inc (CRDF) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch